https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-23 / 2018;7(9):e1476817
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-23 / 2018;7(9):e14768172018-07-23 00:00:002018-07-23 00:00:00Vitamin D deficiency in head and neck cancer patients – prevalence, prognostic value and impact on immune function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-12 / 2018 Jul;7(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-12 / 2018 Jul;7(7)2018-07-12 00:00:002018-07-12 00:00:00Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-03 / 2018;9:809
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-03 / 2018;9:8092018-07-03 00:00:002018-07-03 00:00:00Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-17 / Breast Cancer Res Treat 2018 01;167(2):591-598
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-17 / Breast Cancer Res Treat 2018 01;167(2):591-5982017-10-17 00:00:002017-10-17 00:00:00Serum selenium levels predict survival after breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-21 / Blood Cells Mol. Dis. 2018 03;69:57-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-21 / Blood Cells Mol. Dis. 2018 03;69:57-642017-09-21 00:00:002017-09-21 00:00:00Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-18 / 2017 May;39(5):884-893
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-18 / 2017 May;39(5):884-8932017-04-18 00:00:002017-04-18 00:00:00Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-01 / 2016;62(1):47-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-01 / 2016;62(1):47-522016-01-01 00:00:002016-01-01 00:00:00Vitamin B6 Modifies the Immune Cross-Talk between Mononuclear and Colon Carcinoma Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-07 / PLoS ONE 2015;10(4):e0120228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-07 / PLoS ONE 2015;10(4):e01202282015-04-07 00:00:002015-04-07 00:00:00High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-562013-06-19 00:00:002013-06-19 00:00:00Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-462013-05-14 00:00:002013-05-14 00:00:00Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
